Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 9/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | THRB | P10828 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | CARM1 | Q86X55 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.46 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.46 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21935294 | 0.84 | KLKB1 (0.53) | PTGS2MAPTSMN1; SMN2THRBTP53 | |
| SCHEMBL21879554 | 0.82 | PTGS1 (0.70) | PTGS2MAPTSMN1; SMN2THRBPOLB | |
| SCHEMBL30300474 | 0.78 | PTGS2 (0.47) | PTGS2MAPTSMN1; SMN2THRBPOLB | |
| SCHEMBL21935285 | 0.78 | CCR1 (0.42) | PTGS2MAPTSMN1; SMN2POLBKLKB1 | |
| SCHEMBL20502751 | 0.77 | KLKB1 (0.59) | MAPTSMN1; SMN2POLBTP53KLKB1 | |
| SCHEMBL31420334 | 0.76 | KLKB1 (0.62) | PTGS2MAPTSMN1; SMN2THRBPOLB | |
| SCHEMBL21879588 | 0.76 | KLKB1 (0.62) | PTGS2MAPTSMN1; SMN2THRBPOLB | |
| SCHEMBL6014008 | 0.76 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL20502210 | 0.75 | KDM4E (0.56) | PTGS2MAPTSMN1; SMN2THRBTP53 | |
| SCHEMBL21879532 | 0.75 | KLKB1 (0.52) | PTGS2MAPTSMN1; SMN2THRBPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212157-A1 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | ISTITUTO GIANNINA GASLINI (IT) | 2023-07-06 | — | — | US | disclosed |
| US-20230212157-A1 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | ISTITUTO GIANNINA GASLINI (IT) | 2023-07-06 | — | — | US | disclosed |
| EP-3596067-B1 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2023-06-07 | — | — | EP | disclosed |
| US-20200131157-A1 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | ISTITUTO GIANNINA GASLINI (IT) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212157-A1 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCC5, ABCC1 | PTGS2 2931/4885MAPT 4663/4885SMN1; SMN2 4800/4885 |
| US-20200131157-A1 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCC5, ABCC3 | PTGS2 2979/4885MAPT 4662/4885SMN1; SMN2 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.